Arcturus Therapeutics Holdings Inc. - 8-K Filing

Arcturus Therapeutics announces interim Phase 2 results for ARCT-810 in OTC deficiency and introduces next-gen mRNA platform LUNAR 2.0™ (Items: 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $ARCT

Read the full article at SEC EDGAR

More Regulatory news